Arcadia Biosciences Stock Piotroski F Score

RKDA Stock  USD 6.30  0.21  3.45%   
This module uses fundamental data of Arcadia Biosciences to approximate its Piotroski F score. Arcadia Biosciences F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Arcadia Biosciences. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Arcadia Biosciences financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Arcadia Biosciences Altman Z Score, Arcadia Biosciences Correlation, Arcadia Biosciences Valuation, as well as analyze Arcadia Biosciences Alpha and Beta and Arcadia Biosciences Hype Analysis.
For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.
  
At present, Arcadia Biosciences' Net Debt To EBITDA is projected to increase slightly based on the last few years of reporting. The current year's Debt To Equity is expected to grow to 0.07, whereas Short and Long Term Debt Total is forecasted to decline to about 956.6 K. At present, Arcadia Biosciences' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.32, whereas Price To Sales Ratio is forecasted to decline to 0.69.
At this time, it appears that Arcadia Biosciences' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Decreasing

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Increase

Focus
Long Term Debt Over Assets Change

Lower Leverage

Focus
Change In Outstending Shares

Increase

Focus
Change in Gross Margin

Increase

Focus

Arcadia Biosciences Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Arcadia Biosciences is to make sure Arcadia is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Arcadia Biosciences' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Arcadia Biosciences' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.260.2705
Sufficiently Down
Slightly volatile
Total Current Liabilities4.1 M3.6 M
Fairly Up
Pretty Stable
Non Current Liabilities Total3.2 M3.4 M
Notably Down
Slightly volatile
Total Assets35.9 M19.7 M
Way Up
Slightly volatile
Total Current Assets28.3 M15 M
Way Up
Slightly volatile

Arcadia Biosciences F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Arcadia Biosciences' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Arcadia Biosciences in a much-optimized way.

About Arcadia Biosciences Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

9.76

At present, Arcadia Biosciences' Book Value Per Share is projected to increase significantly based on the last few years of reporting.

Arcadia Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcadia Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcadia Biosciences' managers, analysts, and investors.
Environmental
Governance
Social

About Arcadia Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arcadia Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcadia Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcadia Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:
Check out Arcadia Biosciences Altman Z Score, Arcadia Biosciences Correlation, Arcadia Biosciences Valuation, as well as analyze Arcadia Biosciences Alpha and Beta and Arcadia Biosciences Hype Analysis.
For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.285
Earnings Share
(6.77)
Revenue Per Share
3.802
Quarterly Revenue Growth
(0.04)
Return On Assets
(0.39)
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.